Following a customer-centric approach, the main objective of VIVEbiotech’s Technological Innovation Department is to develop the most productive, functional and regulatory-compliant vector before the production phase in bioreactors.

Improve producer cell lines, including the possibility of genetic modification to:

  • Enhance productivity.
  • Increase tropism.
  • Optimize expansion.
  • Obtain a stable cell line.

Develop new analytical methods to:

  • Better understand our process and/or product.
  • Improve analytical methods for batch release.

Different pseudotyping strategies.


Worldwide licensed technology (WO 2015/078999 A1) consisting of a non-integrative episomal stable lentiviral vector that provides a lasting, stable, consistent expression of the transgene in dividing and non-dividing cells.